Advances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer

Abstract Tumor immunotherapy is praised as “green therapy,” which can attack tumor by mobilizing immune system. By removing the inhibition of immune cells, checkpoint inhibitors help T cells to identify and kill tumor cells. In recent years, more and more attention has been paid to its effectiveness as a tumor therapy with a large number of clinical data. Currently, inhibitors of 2 checkpoints, CTLA‐4 and PD‐1/PD‐L1, have been approved to be listed. In particular, the latter has achieved breakthrough progress in non‐small cell lung cancer in recent years, bringing about changes in the therapeutic strategy of lung cancer, as well as challenges to the evaluation criteria. This article focuses on the latest immunotherapy methods for lung cancer. The purpose of this article is to summarize the development of evidence‐based medicine for lung cancer immunotherapy and to provide help for further understanding of lung cancer immunotherapy.